The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | AML: mutant IDH1 inhibitor HMS-101
Michael Heuser
• 25 Oct 2019
Michael Heuser, MD, Hannover Medical School, Hannover, Germany, discusses the aims, methods and findings of his study of the in vivo efficacy of the mutant IDH1 inhibitor HMS-101 and the structural resolution of a distinct binding site. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
